117 related articles for article (PubMed ID: 18191803)
1. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.
Bowen ME; Ray WA; Arbogast PG; Ding H; Cooper WO
Am J Obstet Gynecol; 2008 Mar; 198(3):291.e1-5. PubMed ID: 18191803
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
Cooper WO
J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Piper JM; Ray WA; Rosa FW
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):429-32. PubMed ID: 1495700
[TBL] [Abstract][Full Text] [Related]
4. Major congenital malformations after first-trimester exposure to ACE inhibitors.
Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.
Morimoto T; Gandhi TK; Fiskio JM; Seger AC; So JW; Cook EF; Fukui T; Bates DW
J Eval Clin Pract; 2004 Nov; 10(4):499-509. PubMed ID: 15482412
[TBL] [Abstract][Full Text] [Related]
7. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
8. Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure.
Chisholm CA; Chescheir NC; Kennedy M
Am J Perinatol; 1997 Oct; 14(9):511-3. PubMed ID: 9394157
[TBL] [Abstract][Full Text] [Related]
9. Outpatient use of cardiovascular drugs during pregnancy.
Andrade SE; Raebel MA; Brown J; Lane K; Livingston J; Boudreau D; Rolnick SJ; Roblin D; Smith DH; Dal Pan GJ; Scott PE; Platt R
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):240-7. PubMed ID: 18200619
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.
Austin PC; Tu JV; Ko DT; Alter DA
CMAJ; 2008 Oct; 179(9):901-8. PubMed ID: 18936455
[TBL] [Abstract][Full Text] [Related]
11. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
Tabacova S; Little R; Tsong Y; Vega A; Kimmel CA
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):633-46. PubMed ID: 14762979
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure.
Tribouilloy C; Rusinaru D; Leborgne L; Peltier M; Massy Z; Slama M
Am J Cardiol; 2008 Mar; 101(5):639-44. PubMed ID: 18308013
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting.
Benedetto U; Sciarretta S; Roscitano A; Fiorani B; Refice S; Angeloni E; Sinatra R
Ann Thorac Surg; 2008 Oct; 86(4):1160-5. PubMed ID: 18805152
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcomes following hospitalisation for a fall in Washington State from 1987 to 2004.
Schiff MA
BJOG; 2008 Dec; 115(13):1648-54. PubMed ID: 18947341
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):240-2. PubMed ID: 9082178
[TBL] [Abstract][Full Text] [Related]
16. Use of prescription medications with a potential for fetal harm among pregnant women.
Andrade SE; Raebel MA; Morse AN; Davis RL; Chan KA; Finkelstein JA; Fortman KK; McPhillips H; Roblin D; Smith DH; Yood MU; Platt R; H Gurwitz J
Pharmacoepidemiol Drug Saf; 2006 Aug; 15(8):546-54. PubMed ID: 16586470
[TBL] [Abstract][Full Text] [Related]
17. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands.
Bakker MK; Jentink J; Vroom F; Van Den Berg PB; De Walle HE; De Jong-Van Den Berg LT
BJOG; 2006 May; 113(5):559-68. PubMed ID: 16637899
[TBL] [Abstract][Full Text] [Related]
18. Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.
Shrim A; Berger H; Kingdom J; Hamoudi A; Shah PS; Koren G
Can Fam Physician; 2005 Oct; 51(10):1335-7. PubMed ID: 16250418
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
20. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
